Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2020)
Historic Cash from Operations for Monopar Therapeutics (MNPR) over the last 4 years, with Q3 2020 value amounting to -$1.3 million.
- Monopar Therapeutics' Cash from Operations fell 11206.62% to -$1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$4.1 million, marking a year-over-year decrease of 4260.87%. This contributed to the annual value of -$6.4 million for FY2024, which is 1850.47% up from last year.
- Per Monopar Therapeutics' latest filing, its Cash from Operations stood at -$1.3 million for Q3 2020, which was down 11206.62% from -$995474.0 recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Cash from Operations registered a high of -$305128.0 during Q2 2017, and its lowest value of -$1.3 million during Q3 2020.
- For the 4-year period, Monopar Therapeutics' Cash from Operations averaged around -$783147.5, with its median value being -$752863.0 (2018).
- The largest annual percentage gain for Monopar Therapeutics' Cash from Operations in the last 5 years was 4982.04% (2018), contrasted with its biggest fall of 15967.43% (2018).
- Over the past 4 years, Monopar Therapeutics' Cash from Operations (Quarter) stood at -$816021.0 in 2017, then soared by 36.37% to -$519212.0 in 2018, then fell by 28.79% to -$668705.0 in 2019, then crashed by 94.49% to -$1.3 million in 2020.
- Its Cash from Operations stands at -$1.3 million for Q3 2020, versus -$995474.0 for Q2 2020 and -$1.1 million for Q1 2020.